NewAmsterdam Pharma Company N.V.

NasdaqGM NAMS

NewAmsterdam Pharma Company N.V. Return on Equity (ROE) for the year ending December 31, 2023: -61.35%

NewAmsterdam Pharma Company N.V. Return on Equity (ROE) is -61.35% for the year ending December 31, 2023, a -1,306.32% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

NewAmsterdam Pharma Company N.V. Return on Equity (ROE) for the year ending December 31, 2022 was -4.36%, a 94.08% change year over year.
NewAmsterdam Pharma Company N.V. Return on Equity (ROE) for the year ending December 31, 2021 was -73.73%.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

NasdaqGM: NAMS

NewAmsterdam Pharma Company N.V.

CEO	Dr. Michael Harvey Davidson FACC, Facp., M.D.
IPO Date	Feb. 9, 2021
Location	Netherlands
Headquarters	Gooimeer 2-35
Employees	62
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Key trends

Past 5 years